Brian Schwartz

Biography

Dr. Schwartz joined ArQule as Chief Medical Officer in July 2008 and in 2013 he took on the responsibility of head of research and development. Dr. Schwartz has more than a decade of experience in the pharmaceutical and biotechnology industries. Prior to joining ArQule, he was senior vice president, clinical and regulatory affairs, and chief medical officer at Ziopharm Oncology where he built and led the clinical, regulatory, and quality assurance departments with responsibilities for the development of new cancer drugs. Prior to Ziopharm, Dr. Schwartz held a number of positions at Bayer Healthcare. His experience in oncology encompassed the clinical development of novel cytostatic, cytotoxic and immunological agents. At Bayer, Dr. Schwartz was a key physician responsible for the global clinical development of sorafenib (Nexavar®) and led the clinical team through a successful Phase 3 trial in renal cell cancer, leading to U.S. Food and Drug Administration (FDA) approval. He has extensive regulatory experience working with the FDA’s Oncology Division, the European Medicines Agency (EMA), and numerous other health authorities. Dr. Schwartz has also been responsible for U.S. clinical and regulatory activities, including Phase 4 studies and interactions with the National Cancer Institute and other oncology cooperative groups. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in industry.  

Research Interest

 Oncology,Pharmaceutical and Biotechnology